Immunocore 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) England and WalesNot Applicable(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 92 Park Drive Milton Park Abingdon, Oxfordshire, United KingdomOX14 4RY(Address of principal executive offices)(Zip Code) +44 1235 438600(Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: *Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer Accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesNo Indicate the number of shares outstanding of each of the issuer’s classes of shares, as of the latest practicable date. As of April 30, 2026, the registrant had 50,865,574 ordinary shares (including ordinary shares in the form of American DepositaryShares) outstanding, par value £0.002. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the "Quarterly Report"), contains forward-looking statements that involve substantialrisks and uncertainties. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,”“would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and“ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Thesestatements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels ofactivity, performance or achievements to be materially different from the information expressed or implied by these forward-lookingstatements. The forward-looking statements and opinions contained in this Quarterly Report are based upon information available to usas of the date of this Quarterly Report and, while we believe such information forms a reasonable basis for such statements, suchinformation may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustiveinquiry into, or review of, all potentially available relevant information. Forward-looking statements include, but are not limited to,statements about: •the therapeutic potential and expected clinical benefits of KIMMTRAK®;•the planned geographic expansion and expansion of patient reach for KIMMTRAK;•the plans for expansion and growth into new melanoma indications, beyond melanoma into other tumor types, andbeyond oncology;•the safety, efficacy and clinical progress of our various ongoing clinical programs and any planned clinical programs,including those for tebentafusp, brenetafusp, IMC-P115C, IMC-R117C, IMC-M113V, IMC-S118AI, and IMC-U120AI;•our ability to continue to generate revenues, which is dependent upon maintaining significant market acceptance amongphysicians, patients and healthcare payors;•our ability to maintain regulatory approval of KIMMTRAK for metastatic uveal melanoma ("mUM") in the UnitedStates, European Union and other territories, as well a